Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis

Area of Science:

• Biomaterials Science
• Pharmacology
• Osteoporosis Research

Background:

• Geniposidic acid (GPA) from Eucommia ulmoides activates farnesoid X receptor (FXR) for bone formation but suffers from low oral bioavailability and poor bone targeting.
• Developing bone-targeted therapies is crucial for treating bone-related diseases like osteoporosis.
• Modern strategies involve modifying drugs with targeting moieties like peptides to enhance efficacy.

Purpose of the Study:

• To synthesize and evaluate a novel bone-targeting conjugate of GPA with an osteoblast-targeting peptide (SDSSD).
• To assess the efficacy of the SGPA conjugate in promoting osteoblast activity and treating osteoporosis in vivo.
• To elucidate the molecular mechanisms underlying SGPA's therapeutic effects on bone formation.

Main Methods:

• Fmoc solid-phase synthesis was used to create the SDSSD-GPA conjugate (SGPA).
• In vitro studies assessed SGPA's cytotoxicity, osteoblastic activity, and mineralization in primary osteoblasts.
• In vivo studies utilized an ovariectomized (OVX) mouse model to evaluate bone mass, histomorphometry, and serum markers.
• Molecular mechanisms involving FXR and RUNX2 activation were investigated.

Main Results:

• SGPA demonstrated targeted accumulation in osteoblasts and bone tissue.
• In vitro, SGPA significantly enhanced osteogenic activity and mineralization compared to GPA.
• In vivo, SGPA increased bone mass, improved bone mineralization rates, and elevated serum bone formation markers (BALP, P1NP).
• SGPA effectively activated the FXR-RUNX2 signaling pathway.

Conclusions:

• SGPA is effectively enriched in osteoblasts and promotes bone formation.
• The SGPA conjugate activates the FXR-RUNX2 signaling pathway, leading to enhanced bone formation and osteoporosis treatment.
• SGPA offers a promising, targeted approach for osteoporosis therapy with improved efficacy and safety.